Answers are grounded in this paper and cite their sources.
Background Pulmonary hypertension (PH) associated with lung disease (Group 3 PH), including interstitial lung disease-associated PH (ILD-PH), is a severe condition with high clinical burden and mortality. However, its epidemiology and real-world burden in France remain insufficiently characterised. Method Using the French National Health Data System (SNDS), this retrospective study identified Group 3 PH and ILD-PH cases between 2017 and 2019 through a published algorithm. For incident ILD-PH patients, incidence, prevalence, survival, treatment patterns, healthcare resource utilisation (HCRU) and costs were assessed through 2022. Results Among 2615 Group 3 PH patients, of whom 1119 had ILD-PH, 759 incident ILD-PH cases were identified, including 551 who underwent right heart catheterisation (RHC). Average annual incidence of ILD-PH was 4.97 per million per year (95% CI 4.36–5.59) and prevalence was 7.35 per million (95% CI 6.60–8.09). 3-year overall survival was 52% (95% CI 48.5–55.8). Nearly half (48%) and 63% received PH- and chronic lung disease-specific treatments, respectively. HCRU included 2.61 inpatient hospitalisations (95% CI 2.54–2.68) and 16.77 general practitioner visits (95% CI 16.59–16.95) per patient-year (PPY). Annual costs reached EUR 12 908.43 for hospitalisations (95% CI EUR 12 903.46–12 913.40) and EUR 10 540.44 for primary care (95% CI EUR 10 535.95–10 544.94) PPY. PH-specific treatments represented the largest share of drug expenditures. Conclusion ILD-PH in France is rare but severe, with significant medical and economic burden. Frequent RHC use reflects adherence to guideline-recommended diagnostic pathways. These findings inform healthcare planning, acknowledging claims-based data limitations.
No takes yet. Share an insight, caveat, or question.
Cottin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: